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Thromboxane A2 receptor blockade hnproves renal function and
histopathology in the post-obstructive kidney. To elucidate the role of the
vasoconstrictor thromboxane A2(TXA2) in post-obstructive nephropa-
thy, we examined the effect of the TXA2 receptor antagonist
GR32191(GR) on renal function and histopathology in the post-ob-
structed kidney (P0K) in rats. Rats pre-treated with 3 or 6 mg/kg i.p. of
OR prior to ureteral obstruction and maintained on b.i.d. doses of GR
were compared to vehicle-treated and sham-operated controls. Renal
hemodynamic, clearance and excretory function were assessed in each
kidney following relief of 24 hours of unilateral ureteral obstruction.
The histology of each kidney was evaluated. Mean clearances of inulin
for the P0K were significantly greater in the treated rats (0.42 0.06
mi/mm at 6 mg/kg) than in controls (0.13 0.04 mI/mm) and a
dose-response effect was observed (P < 0.05). Paraaminohippurate
clearance was increased by >150% and renal vascular resistance was
reduced by 50% in OR treated animals compared with controls (P <
0.05). Histopathologic findings in the untreated P0K were typical of
early obstruction. In the GR treated groups these changes were much
less severe. These data support an important role for TXA2 in the
pathogenesis of post-obstructive nephropathy.
Unilateral ureteral obstruction (UUO) is associated with
marked reductions in renal blood flow (RBF) and glomerular
filtration rate (GFR) in the obstructed kidney [1]. Within 24
hours the obstructed kidney reaches a hemodynamic steady
state which persists for up to 72 hours after relief of obstruction.
Chronic obstruction results in irreversible loss of renal func-
tion. The mechanism by which obstructive nephropathy occurs
remains unknown. However, there is evidence that the ei-
cosanoid thromboxane A2 may play an important role in the
pathogenesis of this disorder.
Thromboxane A2 (TxA2) is a potent vasoconstrictor, bron-
choconstrictor and platelet aggregator [21. Its analogue U46619
produces reductions in renal blood flow and GFR in the normal
rat kidney by increasing renal vascular resistance without
altering the glomerular capillary ultrafiltration coefficient, Kf
[3]. Thromboxane A2 synthesis in the normal kidney is low but
is signfficantly increased in the chronically obstructed kidney
[4-7]. In addition, the obstructed kidney is more sensitive to
exogenous stimulation of thromboxane production when treated
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with a number of physiologically active substances [8]. An
inflammatory cell infiltrate has been observed in the obstructed
kidney which parallels both the rise in urinary thromboxane
levels and the decline in RBF [6]. When this infiltrate is
prevented by prior irradiation, thromboxane levels are less and
RBF is greater than in untreated controls [9]. All of these
observations support the notion that increased activity or
production of thromboxanes are somehow involved in the
mechanism of reduced renal function in obstructive nephropa-
thy.
These points notwithstanding, attempts to show an improve-
ment in renal function following treatment of post-obstructed
kidneys with thromboxane synthase inhibitors have not shown
a consistent effect on post-obstructive renal function. To our
knowledge, only one study has shown significant improvement
in renal function in the unilateral post-obstructed kidney (P0K)
with thromboxane synthase inhibition [10]. Other studies have
not shown an effect, some despite evidence of high degrees of
synthase inhibition [5, 11]. The reasons for this discrepancy are
not obvious but differences in methodology, species studied and
choice of synthase inhibitor may explain these apparently
conflicting results. Another possible confounding factor may be
the activity of the TxA2 precursor, prostaglandin H2 (PGH2),
which has been shown to bind to platelet thromboxane A2
receptors [12] and may exert significant effects at the renal
thromboxane A2 receptor. Indeed, the receptor is often referred
to as the TxA2/PGH2 receptor. The accumulation of PGH2 that
probably occurs with thromboxane synthase inhibition may be
sufficient to stimulate the thromboxane A2 receptor even in the
presence of reduced levels of TxA2 [13, 14].
The purpose of the present study was to investigate the role
of stimulation of the thromboxane A2 receptor in obstructive
nephropathy by observing the effects of its blockade by the
thromboxane receptor antagonist GR32191 ([1R-[la(Z),2/3,3/3,5a]
— (+) — 7 — [5-([l,1'-biphenyl]-4-ylmethoxy)-3-3-hydroxy-2-(1-pi-
peridinyl)cyclopentyl]-4-heptenoic acid). GR32191 has the specffic
advantages of a relatively long half life and prior safe use in human
subjects [15, 16]. Its potency relative to other Tx receptor antag-
onists is high and its action is specific to the thromboxane A2
receptor [17].
Methods
Male Sprague-Dawley rats weighing from 226 to 389 g at the
time of the experiments were used in these studies. All rats had
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free access to water and a standard rodent diet. Prior to ureteral
obstruction, rats were pre-treated with intraperitoneal injection
of GR32191 3 mg/kg (N = 6), 6 mg/kg (N = 6) or an equal
volume of saline vehicle (N = 6). One hour later, the rats were
anesthetized with sodium pentobarbital (50 mg/kg i.p.) and the
left ureter was obstructed with a silk ligature at the ureteroves-
ical junction via a low midline incision. Rats were allowed to
recover from anesthesia and allowed free access to food and
water. The animals were then maintained on twice daily injec-
tions of GR32191 or vehicle in the same dosages as used
initially. A fourth group of untreated rats (N = 4) received a
sham operation,
Twenty-four hours after surgery, the animals were subjected
to acute study. Animals were anesthetized as before, placed on
a thermostatically controlled heating table and a tracheostomy
was performed. A modified multi-lumen catheter was placed in
the right internal jugular vein for administration of drugs and
solutions. Infusions consisted of 0.9% NaCI at 0.9 mI/hr and a
solution of polyfructosan (inulin) 12.5%, paraaminohippurate
(PAH) 1% and NaC1 0.45% at 0.9 ml/hr. After placement of the
jugular catheter, a priming dose of 0.9 ml of each of these
solutions was given, delivering 112.5 mg polyfructosan and 0.9
mg PAH in a total volume of 1.8 ml. Further doses of pento-
barbital were given intravenously as required to maintain
anesthesia. A catheter in the left femoral artery connected to a
Statham pressure transducer allowed continuous measurement
of arterial blood pressure which was recorded on a polygraph
throughout the experiment. A low midline incision was per-
formed and the ureters were cannulated in their distal third (the
left proximal to the ligation).
Following a 45 minute interval to allow the animal to reach a
steady state, urine from each kidney was collected under oil in
tared containers during five consecutive clearance periods each
of 30 minutes duration (sham-operated animals underwent 3
clearance periods). At the midpoint of each clearance period
approximately 400 d of blood was withdrawn from the femoral
catheter and replaced with an equal volume of 6% bovine serum
albumin in 0.9% NaCI. An aliquot of each blood sample was
reserved for measurement of hematocrit. The remainder of the
samples were centrifuged and the plasma was collected. The
rats were then sacrificed with a lethal dose of pentobarbital.
Fig. 1. Mean arterial pressure (BP) as a function of time after release
of ureteral obstruction in sham-operated rats () and in post-ob-
structed rats pre-treated with vehicle (•), GR32191 3 mg/kg (0) or 6
mg/kg (•).
Immediately following euthanasia, the kidneys were removed
and weighed. The kidneys of those rats which had undergone
unilateral ureteral obstruction and release were bisected and
fixed in 10% neutral calcium buffered formalin. The specimens
were processed and stained with hematoxylin and eosin (H &
E). Multiple sections of each kidney were evaluated in a blinded
fashion by a pathologist who did not know which treatment was
given to the animals until all slides were reviewed and histologic
findings recorded. Each specimen was evaluated for evidence
of cortical and medullary inflammation, cellular injury, and
necrosis as well as cast formation. A score from 0 to 4 was
assigned for each factor.
The volume of urine excreted in each timed clearance period
was determined gravimetrically, allowing calculation of urine
flow rate. The concentration of Na was determined for urine
and plasma samples by flame photometry. Concentrations of
polyfructosan were determined for all samples using a micro-
adaptation of an anthrone assay. PAH concentrations were
determined by standard photometric techniques. Standard for-
mulae were used to calculate clearances, renal vascular resis-
tance and filtration fraction. One animal in the group receiving
GR32191, 3 mg/kg, was hemodynamically unstable during the
preparation and was excluded from the calculation of clear-
ances for that group.
Data are expressed as means SEM. Analysis of variance of
repeated measures was used for statistical evaluation and
determination of significance when variance was similar among
treatment groups. Mann-Whitney and Kruskal-Wallis non-para-
metric analysis were used when variance differed among treat-
ment groups. P < 0.05 was considered significant.
Results
Animal and kidney weights are shown in Table 1. No signif-
icant difference in animal weight was found among the four
treatment groups. The weight of the right (that is, contralateral
in UUO rats) kidney did not vary significantly among treatment
Table 1. Body and kidney weights
Treatment
group
Animal
weight
Right
kidney
Left
kidney Weight
g
ShamN = 4 330 36 1.28 0.12 1.29 0.11 0.01 0.08
UUO
Vehicle 297 17 1.40 0.10 1.77 0.lOa 0.36 o.o4N=6
GR32191 288 20 1.28 0.09 1.60 0.08 0.33 o.o'r
3 mg/kgN=6
OR32l9l 333 16 1.42 0.08 1.57 0.09 0.16 0.05
6 mg/kgN=6
E
0
180
160
140
120
100
Weight of the rats and their kidneys after unilateral ureteral obstruc-
tion. Weight refers to the difference in weight between the left and
right kidneys in each group.
a P < 0.05 compared to sham-operated controls 50 100 150 200
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Table 2. Indicies of renal funtion in sham-operated and post-obstructed rats, with and without treatment (mean values sEM)
Treatment group
V
p2/mm
CPAH GFR UNaV
nEq/min
FENa
%
RVR
mm Hg/mi/mm
Filtration
fractionmi/mm
Sham N = 4
Right kidney 7.7 1.8 3.81 0.29 1.51 0.11 95 38 0.04 0.02 19.6 1.9 0.40 0.04
Left kidney 9.2 2.4 3.67 0.51 1.48 0.10 180 78 0.08 0.04 21.3 2.9 0.40 0.08
P0K
Vehicle N 6 4.5 0.9 0.62 0.20a 0.13 0.04k 474 1l5 4.37 l.75 332 168k 0.20 o.o3
GR32191 3 mg/kg 4.6 1.0 1.63 0.20 0.30 0.04 379 152S 0.91 0.35 56.8 10.9 0.18 o.o2
N—5
0R32191 6 mg/kg 6.5 1.0 2.19 0.44 0.42 0.O6 479 usa 0.87 024ab 45,3 70b 0.20 o.ola
N—6
CLK
Vehicle N = 6 16.9 2.6a 5.15 0.6l 1.60 0.15 992 436k 0.46 0.22k 17.3 1.6 0.36 0.04
GR32191 3 mg/kg 19.2 3.6a 4.13 0.35 1.54 0.12 1740 635â 0.76 0.26a 19.1 1.7 0.39 0.04N=5
GR32191 6 mg/kg 15.9 1.8k 4.24 0.36 1.78 0.10 670 ll4 0.26 O.O4 20.4 0.7 0.43 0.02
N=6
Effect of ureteral obstruction and the thromboxane receptor antagonist GR32 191 on the kidneys of sham-operated rats (sham) and the
post-obstructed kidneys (P0K) and contralateral kidneys (CLK) of UUO rats with respect to urine flow (V), PAH clearance (CPAH), glomerular
filtration rate (GFR), absolute sodium excretion (UNaV), fractional sodium excretion (FENa), renal vascular resistance (RVR) and filtration
fraction.
a P < 0.05 compared to sham-operated animals
b P < 0,05 compared to P0K treated with vehicle
c P < 0.05 compared to 0R32191 3 mg/kg
ITTTTTT1I.
Time, minutes
Fig. 2. Effect of pre-treatment with GR32191 3 mg/kg (0) or 6 mg/kg(•)onPAH clearance in the P0K of UUO rats. Symbol (•) is vehicle.
< 0.05 compared to controls.
groups. However, the left kidney (that is, P0K) in the UUO
rats treated with only saline vehicle was significantly heavier
than that of the sham-operated controls (1.77 0.10 g vs. 1.29
0.11 g, P <0.05). The P0K of rats pre-treated with GR32191
also tended to have higher weights but there was a dose
dependent trend toward lower weights in the P0K of the rats
receiving GR32191. Comparison of the differences between the
weights of the right and left kidneys ( wt) in each group
revealed that a significant difference existed between the sham-
operated group and the UUO groups treated with either vehicle
50 100 150 200
or 3 mg/kg of GR32 191 while the group treated with 6 mg/kg of
GR32191 differed from each of these (P < 0.05) and was not
statistically different from the sham-operated group, further
suggesting a dose dependent effect.
The effects of unilateral ureteral obstruction and treatment
with the thromboxane A2 receptor antagonist on mean arterial
pressure are shown in Figure 1. Rats pre-treated with the higher
dose of GR32191 (6 mg/kg) tended to have higher blood pres-
sures initially than the low-dose (3 mg/kg) and control groups
but this difference was not statistically significant. There was no
4.
2
0
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50 100 150
Time, minutes
Fig. 3. Effect of pre-treatment with GR32191 3 mg/kg (0) or GR32191
6 mg/kg (•) on glomerular filtration rate in the P0K of UUO rats.
Symbol (U) is vehicle. p < 0.05 compared to controls, # P < 0.05
compared to GR32191 3 mg/kg.
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significant difference between blood pressures in the post-
obstructed rats and in sham-operated controls over the periods
measured. Blood pressure remained stable over time in all
experimental groups.
There was no difference in hematocrit among the three
groups of post-obstructed animals. A slight decline in hemato-
crit in all three groups over time was not statistically significant.
The hematocrit of sham-operated rats was not significantly
different from that of post-obstructed animals.
The effects of unilateral ureteral obstruction on indices of
renal function in the post-obstructed kidney are shown in Table
2. The values shown are calculated means of the measured
values over five clearance periods. Most parameters did not
change significantly overtime. Those that did, all of which were
in the post-obstructed kidney, are shown graphically in the
figures that follow.
Mean urine flow rates in post-obstructed kidneys tended to be
less than in sham-operated controls although the difference was
not significant. Pre-treatment with GR32191 did not signifi-
cantly change flow rates, Urine flow rates in the contralateral
kidney were more than twice that observed in the right kidney
of sham operated rats ranging from 15.9 1.8 to 19.2 2.6
dImin vs. 7.7 1.8 d/min and were unaffected by pre-
treatment with GR32191.
Mean clearance of PAH, an index of renal plasma flow was
0.62 0.20 mllmin in the post-obstructed kidneys of rats
pre-treated with only saline vehicle or 17% of that observed in
the left kidney of sham-operated controls (3.67 0,51 mI/mm).
In contrast, PAH clearance was significantly greater in the
post-obstructed kidneys of rats pre-treated with either 3 mg/kg
or 6 mg/kg of GR32191, 1.63 0.20 and 2.19 0.44 mI/mm,
respectively (P < 0.05; Fig. 2). Moreover, PAH clearance
improved progressively with time in the P0K of treated rats
while changing little in the control group. Although there
appeared to be a dose-response effect, no significant difference
was observed. Conversely, PAH clearance was significantly
greater in the contralateral kidneys of post-obstructed rats
treated with vehicle only (5.15 0.61 mI/mm) than in the right
kidney of sham-operated controls (3.81 0.29 mI/mm; P =
0.03). Pre-treatment with 3 mg/kg or 6 mg/kg of GR32l9l
resulted in lower PAH clearances in the contralateral kidney,
4.13 0.35 and 4.24 0.36 mI/mm, respectively, which were
not statistically different from those seen in sham-operated rats.
GFR was significantly reduced in the post-obstructed kidneys
of rats pre-treated with vehicle only (0.13 0.04 mlJmin) with
mean values reaching less than 10% of those seen in sham-
operated rats (1.5 0.10 ml/min). However, pre-treatment of
rats with GR32191 3 mg/kg or 6 mg/kg resulted in significant
increases in GFR in the post-obstructed kidney (0.30 0.04 and
0.42 0.06 mi/mm, respectively) and a dose/response effect
was observed (P < 0.05; Fig. 3). As with PAH clearance, GFR
continued to improve with time in pre-treated rats while little
200 change in GFR was observed in the vehicle treated group.
Neither unilateral ureteral obstruction nor thromboxane recep-
tor antagonist resulted in a significant effect on GFR in the
contralateral kidney in any of the UUO groups.
A fifteen-fold increase in mean renal vascular resistance
(RVR) was observed in the post-obstructed kidney of rats
treated with the vehicle relative to sham-operated controls.
Although a rapid decline in the RVR occurred in this group,
values remained elevated throughout the course of the experi-
ment (Fig. 4). Rats pretreated with 3 mg/kg or 6 mg/kg of
GR32191 had significantly lower RVR than the vehicle treated
group (56.8 10.9 and 45.3 7.0 mm Hg• mm/mI, respec-
tively, versus 332 168 mm Hg• mm/mI; P < 0.05, Table 2).
The difference between the high dose and the low dose treat-
ment groups was not significant. No significant change was
observed in the contralateral kidney with either obstruction or
GR32191 treatment.
Filtration fraction in the P0K of all three treatment groups
was about half of that seen in the sham-operated group and this
effect was unaltered by GR32 191. Filtration fraction in the CLK
was not different from that of the sham operated group.
Histopathologic findings are summarized in Table 3. In the
P0K of animals treated only with vehicle, the classic findings of
early obstruction were seen (Fig. 5). The congested and edem-
atous cortex contained tubules that were markedly dilated;
some were filled with proteinaceous debris and casts. There
was a moderate infiltrate of inflammatory cells, including lym-
phocytes, histiocytes and occasional neutrophils. Histological
markers of tubule cell injury were seen frequently in the vehicle
treated P0K. These changes included hydropic degeneration,
loss of apical microvilli, swelling of the tubule cells and focal
necrosis of individual tubule cells. In the renal medulla, there
was frank necrosis of the nephron loops in all vehicle treated
P0K, involving 20 to 80% of the medulla. Inflammatory mill-
trates were only occasionally present in the medulla, even in
areas of widespread tubular necrosis. In contrast, in the P0K
from animals treated with 6 mg/kg GR32191, the histologic
markers of obstruction and renal failure were dramatically
decreased (Fig. 6). The renal cortex had fewer tubules under-
going dilation and the degree of dilation was less. Proteinaceous
debris within individual tubules was less and cast formation was
rare. The degree of edema was less, as demonstrated by
comparing Figures SA and 6A, taken at identical magnification.
No definitive areas of cortical tubule necrosis were seen in any
1000
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Fig. 4. Effect of pre-treatment with GR32191 3 mg/kg (0) or GR32191
6 mg/kg (•) on renal vascular resistance (RVR) in the P0K of UUO
rats, Symbol (•) is vehicle. *D < 0.05 compared to controls.
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Table 3. Scoring of histopathologic findings
Specimen
Inflammation Cell injury Necrosis
Cortex Medulla Cortex Medulla Cortex Medulla Casts
CLK vehicle
P0K vehicle
P0K GR32191 3 mg/kg
P0K GR32191 6 mg/kg
0.5
2.8
1.7
0.7
0
0.8
0.3
0.2
0.5
2.7
1.5
0.7
0.3
3.5
1.5
0.7
0
2.3
0.3
0
0
3.5
1.5
0.7
0.1
2.3
0.8
0.3
Each specimen was evaluated for cortical and medullary inflammation, cell injury, necrosis and cast formation. For each parameter a score was
assigned, from 0 (no evidence or absent) to 4 (severe). Mean values are shown for contralateral kidneys (CLK) of vehicle treated rats and for
post-obstructed kidneys (P0K) of rats treated with the vehicle or GR32 191 3 mg/kg or 6 mg/kg.
Fig. 5. Post-obstructed kidney of vehicle treated UUO rat, A. Renal cortex demonstrates tubular dilation and proteinaceous debris in many of the
dilated tubules. 100 x. B. Histologic evidence of tubular damage with vacuolar change, loss of microvilli, focal necrosis and sloughing of tubular
cells into the lumen. 480 x. C. Aggregates of inflammatory cells as well as a diffuse increase in interstitial mononuclear cells are seen in the renal
cortex. 250 x. D. Frank necrosis of the medulla with residual casts and debris filling the tubular and ductal lumen. Inflammatory infiltrates are less
prominent in the medullary region than in the cortex. 250 x.
of the treated kidneys and the hydropic changes and swelling of GR32191 treated animals and consisted of a very mild, diffuse
individual tubule cells was less than in the vehicle treated interstitial infiltrate of lymphocytes. Most impressively, the
kidney. The inflammatory response was decreased in the necrosis of the medullary tubules and loops was markedly less,
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Fig. 6. Post-obstructed kidney of UUO rat treated with GR32191 6 mg/kg. A. Renal cortex. A small degree of tubular dilation and lumen debris
is seen. 100 x. B. Cortex. Note preservation of apical microvilli and reduction in the vacuolar changes seen in the untreated P0K. Necrosis and
sloughing of tubular cells was less common in the treated animals. 480 x. C. Rare inflammatory cells consisting primarily of lymphocytes. 480 x.
D. Renal medulla. Only minimal histologic changes are present. 250 X.
with only occasional areas of focal necrosis in some P0K. In
two of the six P0K, no evidence of medullary necrosis was
seen. In animals receiving 3 mg/kg GR32191, changes interme-
diate to these were seen, that is, some tubular dilation and cast
formation, focal cortical tubular cell injury and medullary
necrosis were present which were less than in the vehicle
treated but more than in the higher dosed animals. As presented
in Table 3, when the numerical assessment of histologic mark-
ers of injury were compared, significant differences were noted
between the CLK and P0K, as well as the P0K vehicle treated
and the P0K GR31291 treated animals. There were no signifi-
cant differences between the P0K kidney treated with 6 mg/kg
GR3 1291 and the respective contralateral kidneys, reflecting the
improvement noted in renal function with treatment.
Discussion
In the present study, we have observed a significant improve-
ment in renal function in the P0K of rats pre-treated with the
TxA2 receptor antagonist GR32191 as manifested by increases
in PAH clearance and GFR and reductions in RVR. In concert
with the results of Yarger, Shocken and Harris [101, these
findings support a significant role for thromboxane A2 and/or
prostaglandin H2 in post-obstructive nephropathy. The effect of
GR32191 on GFR in the post-obstructed kidney was dose
dependent. Similar trends were observed with respect to PAH
clearance and RVR but the differences between low dose and
high dose treatment groups were not significant.
Normal renal hemodynamic function was not fully restored
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by treatment with GR32191, an observation for which several
explanations are possible. We have found that the effect of
TxA2 blockade depends not only on the dose of antagonist used
but also the time elapsed after release of ureteral obstruction. It
is possible that, after a longer interval of recovery, renal blood
flow and glomerular filtration may have been further improved.
The dose of GR32191 used reflects previously reported doses.
Thomas and Lumley reported that in human subjects, a single
dose of 0.5 mg/kg of GR32 191 produced a 100-fold shift of the
dose-response curve of the TxA2 mimetic U46619 with respect
to platelet aggregation [16]. Rossini et al found that pre-
treatment of rats with GR32191 3 mg/kg b.i.d. was sufficient to
prevent reductions in GFR produced by U46619 and cyclospo-
tine [18]. To establish whether the maximum therapeutic effect
of GR32 191 was achieved in our model at the dose reported by
Rossini et al, we included groups of rats treated with both 3
mg/kg and a higher dose of 6 mg/kg.
Filtration fraction in the P0K was decreased relative to that
seen in the CLK and in sham-operated controls. Since GR32191
had no effect on filtration fraction, it seems probable that the
effects of TxA2 on the renal microvasculature are not specific to
a particular vascular segment.
The difference between the weights of the post-obstructive
and contralateral kidneys in rats following unilateral ureteral
obstruction has been reported previously [11]. This observation
is consistent with the known inflammatory response following
UUO [6] and corresponds to the presence of edema on histo-
logic examination and perhaps the inflammatory infiltrate as
well. Of particular interest, the smaller weight difference be-
tween the two kidneys in rats pretreated with a TxA2 antagonist
correlates well with the attenuation of these findings in the P0K
of the treated animals. Thromboxane A2, although not generally
considered to be a chemotactic agent, has recently been impli-
cated in this regard by studies which demonstrate that throm-
boxanes mediate neutrophil diapedesis following ischemic in-
jury [19]. Harris et al concluded that thromboxane production
in the P0K was the result of an inflammatory infiltrate [9]. Our
observations have shown that blockade of the TxA2 receptor is
sufficient to markedly reduce the inflammatory response and
suggest that the inflammatory infiltrate seen in unilateral ure-
teral obstruction is dependent, in part, on increased thrombox-
ane A2 synthesis.
Thromboxane A2 is probably not the only substance respon-
sible for the changes that occur in post-obstructive nephropa-
thy. Angiotensin II, in particular, appears to play a predominant
role. Angiotensin converting enzyme inhibition has been shown
to improve function in the P0K and in some other models of
obstructive nephropathy [17, 20—22]. Following unilateral re-
lease of bilateral obstruction, the effects of inhibition of angio-
tensin II and TxA2 synthesis are cumulative, suggesting that
more than one mechanism may be involved [22]. It should also
be noted in this regard that the renal vasoconstnctor effect of
angiotensin II may be mediated in part by thromboxane A2 [23].
The vasodilator substances bradykinin (BK), platelet activating
factor (PAF), atrial natriuretic peptide and PGE2 have also been
implicated in the pathogenesis of obstructive nephropathy.
PGE2 appears to be responsible for maintaining renal perfusion
in the hydronephrotic kidney in the presence of high levels of
vasoconstrictor substances and its withdrawal results in further
declines in renal blood flow [24, 25]. The roles of BK and PAF
are not as well defined although there is some evidence that
they are involved in stimulating thromboxane A2 production in
the hydronephrotic kidney [8, 26—28]. Atrial natnuretic peptide
also appears to be important in the natriuresis and diuresis
which occurs after relief of bilateral ureteral obstruction [29]
and may also be important in maintaining renal blood flow [30].
Thus, it seems possible that some of the effects of these
substances may be mediated by thromboxane A2.
We conclude that thromboxane A2 and/or prostaglandin H2
play an important role in the pathogenesis of post-obstructive
nephropathy and that thromboxane A2 receptor antagonists are
capable of preventing some of the deleterious effects of this
renal insult. Perhaps more attractive is the suggestion that the
potential exists for a clinical role for thromboxane A2 antago-
nists in the prevention and treatment of acute obstructive
nephropathy in humans.
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